JCM Figure table search 04
Home Help [Feedback] [For Subscribers] [Archive] [Search] [Contents]
This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Other Versions of this Article:
JCM.01305-06v1
44/11/3915    most recent
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow Copyright Information
Right arrow Books from ASM Press
Right arrow MicrobeWorld
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Castle, P. E.
Right arrow Articles by Kornegay, J.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Castle, P. E.
Right arrow Articles by Kornegay, J.
Journal of Clinical Microbiology, November 2006, p. 3915-3917, Vol. 44, No. 11
0095-1137/06/$08.00+0     doi:10.1128/JCM.01305-06
Copyright © 2006, American Society for Microbiology. All Rights Reserved.

Pilot Study of a Commercialized Human Papillomavirus (HPV) Genotyping Assay: Comparison of HPV Risk Group to Cytology and Histology{triangledown}

Philip E. Castle,1* Mark Sadorra,2 Francisco Garcia,3 E. Blair Holladay,4 and Janet Kornegay2

Division of Cancer Epidemiology, National Cancer Institute, NIH, DHHS, Bethesda, Maryland,1 Roche Molecular Systems, Alameda, California,2 University of Arizona Health Sciences Center, Tucson, Arizona,3 Medical University of South Carolina, Charleston, South Carolina4

Received 26 June 2006/ Returned for modification 8 August 2006/ Accepted 30 August 2006

We evaluated a commercialized PCR assay, Linear Array, that detects 37 human papillomavirus (HPV) genotypes, using a sample of liquid cytology specimens (n = 534). We found a strong association of an increasing level of HPV risk (HPV type 16 [HPV16] > HPV18 > other carcinogenic types > noncarcinogenic types > negative specimens) with increasing severities of cytologic interpretations (PTrend < 0.0005) and histologic diagnoses (PTrend < 0.0005).


* Corresponding author. Mailing address: Division of Cancer Epidemiology and Genetics, National Cancer Institute, 6120 Executive Blvd., Room 5123, EPS MSC 7234, Bethesda, MD 20892-7234. Phone: (301) 435-3976. Fax: (301) 402-0916. E-mail: castlep{at}mail.nih.gov.

{triangledown} Published ahead of print on 13 September 2006.


Journal of Clinical Microbiology, November 2006, p. 3915-3917, Vol. 44, No. 11
0095-1137/06/$08.00+0     doi:10.1128/JCM.01305-06
Copyright © 2006, American Society for Microbiology. All Rights Reserved.




This article has been cited by other articles:




Home Help [Feedback] [For Subscribers] [Archive] [Search] [Contents]
Antimicrob. Agents Chemother. Clin. Microbiol. Rev.
Clin. Vaccine Immunol. ALL ASM JOURNALS

Copyright © 2006 by the American Society for Microbiology. All rights reserved.